低强度体外冲击波治疗联合或不联合药物治疗慢性前列腺炎/慢性盆腔疼痛综合征的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入12项随机对照试验共651例患者,评估低强度体外冲击波治疗(Li-ESWT)联合或不联合药物治疗慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的疗效与安全性。结果显示Li-ESWT组在治疗结束时及治疗后1、4、12、24周的总NIH-CPSI评分、疼痛域评分及生活质量评分均显著低于对照组,且联合药物治疗的改善更持久、幅度更大。结论认为Li-ESWT安全、无创、有效,推荐广泛用于临床实践。
要点
- Li-ESWT可显著降低CP/CPPS患者的总NIH-CPSI、疼痛域及生活质量评分,并持续至治疗后24周。
- 联合药物治疗的评分降低幅度更大、持续时间更长。
- Li-ESWT组VAS、IIEF及IPSS评分在多个随访时间点较对照组显著改善。
核心结论
- Li-ESWT是CP/CPPS患者安全、无创、有效的治疗选择,无论是否联合药物治疗,推荐广泛用于临床实践。
研究设计与样本
- 系统评价与Meta分析,检索PUBMED、Cochrane Library和Web of Science数据库自建库至2022年2月的随机对照试验,共纳入12项随机对照研究、651例患者。
主要发现
- Li-ESWT组在治疗结束时及治疗后1、4、12、24周的总NIH-CPSI评分、疼痛域评分及生活质量评分均显著低于对照组,且较基线显著降低。
- 亚组分析中,Li-ESWT联合药物治疗较Li-ESWT单药治疗的评分降低幅度更大、持续时间更长。
- Li-ESWT组VAS评分在治疗结束时及治疗后1、4、12周较对照组显著改善。
- Li-ESWT组IIEF评分在治疗后4、12、24周较对照组显著改善。
- Li-ESWT组IPSS评分在治疗结束时及治疗后1、4、12周较对照组显著改善。
关键数值与推荐
- 采用美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、视觉模拟评分法(VAS)、国际勃起功能指数(IIEF)和国际前列腺症状评分(IPSS)评估症状改善。
临床怎么用
- 作者认为Li-ESWT安全、无创、有效,无论是否联合药物治疗,推荐广泛用于CP/CPPS的临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We performed this systematic review and meta-analysis to investigate the efficacy and safety of Li-ESWT combined with or without medications for patients with Chronic prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). METHODS: A comprehensive search was conducted of PUBMED, Cochrane Library, and Web of Science databases from inception to February 2022 for randomized controlled trials (RCTs) assessing the efficacy and safety of Li-ESWT with or without the combination of medications compared with the control group. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), Visual Analogue Scale/Score (VAS), International Index of Erectile Function (IIEF), and International prostate symptom score (IPSS) were used to assess the improvements of symptoms in CP/CPPS patients. RESULTS: 651 patients from 12 randomized controlled studies were included in this study. The total NIH-CPSI scores, pain domain scores, and quality of life (QOL) scores were significantly lower in the Li-ESWT group than those in the control group at the termination of treatment, and 1, 4, 12, and 24 weeks after treatment. And these scores were significantly reduced in the Li-ESWT group than in baselines. In the subgroup analysis, reductions of these scores lasted longer and were greater in Li-ESWT combined with medications than in Li-ESWT alone. In the Li-ESWT group, the VAS score; IIEF score; and IPSS score were significant improvements than those in control group at the termination of treatment, and 1, 4, and 12 weeks after treatment; 4, 12, and 24 weeks after treatment; and 1, 4, and 12 weeks after treatment, respectively. CONCLUSIONS: Li-ESWT is a safe, non-invasive, and effective option for patients with CP/CPPS, whether combined with medications or not, should be recommended for widespread use in clinical practice.
引用
- Kong X, Hu W, Dong Z, et al. The efficacy and safety of low-intensity extracorporeal shock wave treatment combined with or without medications in Chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 35798855. doi:10.1038/s41391-022-00571-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。